Keros Therapeutics Reports First Quarter 2022 Financial Results
LEXINGTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”)…
News
IN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT 25th Annual Meeting
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical…
Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress
Conference Call and Live Audio Webcast Scheduled for Thursday, May 12, 2022, 5:00 p.m. ET…
Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on…
InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV
Study will use delta-9 dominant THCV manufactured by InMed’s subsidiary BayMedica Assesses key health outcomes…
Radius Health, Inc. First Quarter 2022 Results
Q1 2022 TYMLOS® product net revenue of $43 million vs. $45 million in Q1 2021°…
HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary and Versatile TOBI™ Platform At the 105th Annual Meeting of the American Association of Immunologists
Cytokine-Based Fusion Proteins to Activate and Expand Memory-Like NK Cells Without Using Feeder CellsSufficient for Off-the-Shelf…
SIGA Declares Special Dividend of $0.45 Per Share
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a…
BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update
–Completed sale to Sentynl Therapeutics of BridgeBio’s NULIBRY™ (Fosdenopterin) for Injection –Updated strategic collaboration with…
Acerus To Report Q1-2022 Financial Results And Host Investor Call
TORONTO, May 05, 2022 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCD) will announce its…
Selecta Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
– Phase 1 trial of SEL-302 remains on track to initiate in the second half…
Context Therapeutics® Announces Poster Presentation at the Upcoming 2022 ASCO Annual Meeting
Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates monotherapy clinical activity in advanced granulosa…
Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates
Reaffirms milestone timing for Phase 2 clinical trial of AVTX-002 in non-eosinophilic asthma (NEA) and…
Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update
Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track Well…
XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events
Earned a $2 million milestone from Rezolute as it dosed the final patient in a…
Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12
GAITHERSBURG, Md., May 05, 2022 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical…
Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society
Sorbitol correlates with disease severity in patients with SORD Deficiency AT-007 treatment substantially reduced sorbitol…
Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress
Presented updated interim data from ongoing Phase 1 study in patients with transthyretin (ATTR) amyloidosis…
First Orion and PacificEast Partner to Provide Branded Communication to Enterprises
Data services company to leverage First Orion’s industry-leading INFORM product to increase customer engagement rate…
Emerging Markets Report: The Tipping Point
An Emerging Markets Sponsored Commentary ORLANDO, Fla., May 05, 2022 (GLOBE NEWSWIRE) — In his…